Croda’s Avanti Polar Lipids partners with NovoArc to expand lipid offering for pharma research
- Avanti Polar Lipids, a Croda subsidiary, will collaborate with NovoArc to expand a catalogue of more than 2,000 lipids for the global pharmaceutical research market.
- NovoArc’s advanced lipid technologies are designed to provide improved stability across varied conditions and differ from conventional drug delivery materials.
- The technologies may enable new formulation approaches and administration routes, including oral delivery for complex therapeutics that typically require injectables.
- Products will be available initially for research use, with development aimed at supporting future large-scale manufacturing as programmes progress toward clinical and commercial stages.
Partnership scope
Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, has entered into a strategic collaboration with NovoArc GmbH to expand its range of more than 2,000 lipids for the global pharmaceutical research market.
Technology characteristics
NovoArc’s advanced lipid technologies differ from conventional drug delivery materials and are designed to provide improved stability in a wide range of conditions, potentially enabling formulation approaches not feasible with standard materials.
Applications and delivery options
By broadening access through Avanti Research’s global platform, customers will be able to explore delivery options for complex medicines, including mRNA, protein and peptide-based therapies, and investigate alternative administration routes such as oral delivery for therapies that have traditionally required injection.
Commercial rollout and strategic intent
Initially the products will be available for research use; ongoing development will focus on supporting future large-scale manufacturing capabilities as customer programmes progress towards clinical and commercial stages, and the agreement aligns with Croda’s growth strategy in high-value pharmaceutical technologies.
Source: Croda
